KAKEN PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,407 JPY | +0.53% |
|
-0.21% | +1.55% |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 199,785 | 195,756 | 166,112 | 147,114 | 138,463 | 129,023 | - | - |
| Enterprise Value (EV) 1 | 145,105 | 126,285 | 92,657 | 76,340 | 68,053 | 129,023 | 129,023 | 129,023 |
| P/E ratio | 11.3 x | 10.2 x | 12.5 x | 15.5 x | 25.5 x | 17.2 x | 19.8 x | 24.9 x |
| Yield | 2.98% | 2.98% | 3.46% | 3.86% | 4.06% | 4.4% | 4.4% | 4.4% |
| Capitalization / Revenue | 2.12 x | 2.19 x | 2.22 x | 1.93 x | 1.9 x | 1.77 x | 1.84 x | 1.94 x |
| EV / Revenue | 2.12 x | 2.19 x | 2.22 x | 1.93 x | 1.9 x | 1.77 x | 1.84 x | 1.94 x |
| EV / EBITDA | 7.47 x | 6.79 x | 8.26 x | 7.53 x | 11.1 x | 11.5 x | 13 x | 15.7 x |
| EV / FCF | 13.6 x | 7.6 x | 14.3 x | 27 x | 20.9 x | 16.1 x | 16.9 x | 20.4 x |
| FCF Yield | 7.36% | 13.2% | 7.01% | 3.7% | 4.79% | 6.22% | 5.91% | 4.9% |
| Price to Book | 1.65 x | 1.52 x | 1.22 x | 1.07 x | 1.02 x | 0.93 x | 0.92 x | 0.92 x |
| Nbr of stocks (in thousands) | 39,719 | 38,918 | 38,319 | 37,819 | 37,473 | 37,870 | - | - |
| Reference price 2 | 5,030 | 5,030 | 4,335 | 3,890 | 3,695 | 3,407 | 3,407 | 3,407 |
| Announcement Date | 5/9/19 | 5/22/20 | 5/7/21 | 5/11/22 | 5/10/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 94,165 | 89,232 | 74,979 | 76,034 | 72,984 | 72,700 | 70,200 | 66,600 |
| EBITDA 1 | 26,745 | 28,824 | 20,106 | 19,545 | 12,429 | 11,201 | 9,901 | 8,201 |
| EBIT 1 | 24,592 | 26,512 | 17,788 | 17,064 | 7,998 | 8,600 | 7,400 | 5,800 |
| Operating Margin | 26.12% | 29.71% | 23.72% | 22.44% | 10.96% | 11.83% | 10.54% | 8.71% |
| Earnings before Tax (EBT) 1 | 24,922 | 26,592 | 18,657 | 13,885 | 6,817 | 9,100 | 7,900 | 6,300 |
| Net income 1 | 17,775 | 19,370 | 13,405 | 9,549 | 5,440 | 7,620 | 6,620 | 5,280 |
| Net margin | 18.88% | 21.71% | 17.88% | 12.56% | 7.45% | 10.48% | 9.43% | 7.93% |
| EPS 2 | 445.8 | 494.9 | 347.4 | 251.4 | 144.8 | 197.9 | 171.9 | 137.1 |
| Free Cash Flow 1 | 14,705 | 25,744 | 11,651 | 5,448 | 6,626 | 8,023 | 7,622 | 6,322 |
| FCF margin | 15.62% | 28.85% | 15.54% | 7.17% | 9.08% | 11.04% | 10.86% | 9.49% |
| FCF Conversion (EBITDA) | 54.98% | 89.31% | 57.95% | 27.87% | 53.31% | 71.63% | 76.98% | 77.09% |
| FCF Conversion (Net income) | 82.73% | 132.91% | 86.92% | 57.05% | 121.8% | 105.29% | 115.14% | 119.73% |
| Dividend per Share 2 | 150.0 | 150.0 | 150.0 | 150.0 | 150.0 | 150.0 | 150.0 | 150.0 |
| Announcement Date | 5/9/19 | 5/22/20 | 5/7/21 | 5/11/22 | 5/10/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 45,170 | 36,789 | 37,588 | 20,120 | 18,197 | 36,819 | 18,754 | 18,150 | 36,171 | 18,514 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 13,744 | 9,782 | 9,036 | 4,853 | 4,056 | 8,209 | 4,185 | 3,293 | 5,512 | 3,361 |
| Operating Margin | 30.43% | 26.59% | 24.04% | 24.12% | 22.29% | 22.3% | 22.32% | 18.14% | 15.24% | 18.15% |
| Earnings before Tax (EBT) 1 | 13,623 | 10,365 | 9,436 | 5,021 | 4,008 | 8,229 | 4,412 | 3,451 | 5,658 | 3,562 |
| Net income 1 | 9,547 | 7,226 | 6,721 | 3,525 | 2,907 | 5,964 | 3,185 | 2,510 | 4,068 | 2,607 |
| Net margin | 21.14% | 19.64% | 17.88% | 17.52% | 15.98% | 16.2% | 16.98% | 13.83% | 11.25% | 14.08% |
| EPS 2 | 242.6 | 186.2 | 176.2 | 93.17 | 76.91 | 158.3 | 84.97 | 66.99 | 108.2 | 68.92 |
| Dividend per Share | 75.00 | 75.00 | 75.00 | - | - | 75.00 | - | - | 75.00 | - |
| Announcement Date | 11/6/19 | 11/5/20 | 11/4/21 | 2/3/22 | 8/3/22 | 11/8/22 | 2/3/23 | 8/4/23 | 11/8/23 | 2/6/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 54,680 | 69,471 | 73,455 | 70,774 | 70,410 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 14,705 | 25,744 | 11,651 | 5,448 | 6,626 | 8,023 | 7,622 | 6,322 |
| ROE (net income / shareholders' equity) | 15.1% | 15.5% | 10.1% | 7% | 4% | 5.5% | 4.7% | 3.7% |
| ROA (Net income/ Total Assets) | 16.2% | 17.2% | 11.3% | 10.7% | 5.27% | 4.5% | 3.9% | 3.1% |
| Assets 1 | 109,760 | 112,808 | 118,148 | 89,413 | 103,323 | 169,333 | 169,744 | 170,323 |
| Book Value Per Share 2 | 3,050 | 3,301 | 3,556 | 3,642 | 3,636 | 3,682 | 3,704 | 3,691 |
| Cash Flow per Share 2 | 511.0 | 565.0 | 407.0 | 317.0 | 213.0 | 263.0 | 235.0 | 197.0 |
| Capex | 1,908 | 1,724 | 2,729 | 2,282 | 2,789 | - | - | - |
| Capex / Sales | 2.03% | 1.93% | 3.64% | 3% | 3.82% | - | - | - |
| Announcement Date | 5/9/19 | 5/22/20 | 5/7/21 | 5/11/22 | 5/10/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,407
JPY
Average target price
3,500
JPY
Spread / Average Target
+2.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.55% | 820M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4521 Stock
- Financials Kaken Pharmaceutical Co., Ltd.
